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ABSTRACT
Objective Liver stiffness measurement (LSM) is a tool used 
to screen for significant fibrosis and portal hypertension. The 
aim of this retrospective multicentre study was to develop an 
easy tool using LSM for clinical outcomes in advanced chronic 
liver disease (ACLD) patients.
Design This international multicentre cohort study 
included a derivation ACLD patient cohort with valid two- 
dimensional shear wave elastography (2D- SWE) results. 
Clinical and laboratory parameters at baseline and during 
follow- up were recorded. LSM by transient elastography 
(TE) was also recorded if available. The primary outcome 
was overall mortality. The secondary outcome was the 
development of first/further decompensation.
Results After screening 2148 patients (16 centres), 1827 
patients (55 years, 62.4% men) were included in the 2D- SWE 
cohort, with median liver SWE (L- SWE) 11.8 kPa and a model 
for end stage liver disease (MELD) score of 8. Combination 
of MELD score and L- SWE predict independently of mortality 
(AUC 0.8). L- SWE cut- off at ≥20 kPa combined with MELD 
≥10 could stratify the risk of mortality and first/further 
decompensation in ACLD patients. The 2- year mortality and 
decompensation rates were 36.9% and 61.8%, respectively, 
in the 305 (18.3%) high- risk patients (with L- SWE ≥20 kPa 
and MELD ≥10), while in the 944 (56.6%) low- risk patients, 
these were 1.1% and 3.5%, respectively. Importantly, this 
M10LS20 algorithm was validated by TE- based LSM and in 
an additional cohort of 119 patients with valid point shear 
SWE- LSM.
Conclusion The M10LS20 algorithm allows risk 
stratification of patients with ACLD. Patients with L- SWE 
≥20 kPa and MELD ≥10 should be followed closely and 
receive intensified care, while patients with low risk may 
be managed at longer intervals.
Significance of this study
What is already known on this subject?
 ► To date, the existing tools to stratify liver 
disease patients into different risks for clinical 
outcomes, such as the model for end- stage 
liver disease (MELD), may fail to predict the 
outcome, especially in well- compensated 
patients.
 ► The value of liver shear wave elastography 
(L- SWE) has only been established in the 
classification of liver fibrosis and clinically 
significant portal hypertension.
 ► No studies have assessed the prognostic value 
of SWE for different etiologies and stages of 
liver disease.
What are the new findings?
 ► This international multicenter cohort study 
provides an efficient and easy algorithm 
(M10LS20 algorithm) for risk stratification of 
advanced chronic liver disease (ACLD) with 
the combination of MELD with liver stiffness 
measured by shear wave elastography (SWE).
 ► The combined MELD 10 and liver- SWE (L- 
SWE) 20kPa cutoff (M10LS20) algorithm 
was confirmed in compensated and 
decompensated patients and was validated by 
TE measurements. It was externally validated in 
an addtional cohort of patients with point SWE.
 ► This M10LS20 algorithm provides early 
identification of at- risk patients and allows 
for early treatment, filling the gap in the risk 
stratification for complications and mortality in 
patients with ACLD.
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BACKGROUND
Advanced chronic liver disease (ACLD) is associated with high 
mortality due to decompensations, which are consequences of 
liver failure and portal hypertension.1 In these patients, predictors 
of outcomes are needed to stratify care and to allocate specific 
therapy and liver transplantation. The model for end- stage liver 
disease (MELD) is widely used to predict the prognosis of liver 
cirrhosis patients.2–5 An MELD score above 15 is usually an indi-
cation of evaluation for liver transplantation. However, since the 
MELD score was originally designed to predict 90- day mortality 
after transjugular intrahepatic portosystemic shunt, it may fail 
to predict the outcome, especially in patients with compensated 
cirrhosis, who have a lower MELD score.6
Liver stiffness measurement (LSM) by transient elastog-
raphy (TE), point shear wave elastography (p- SWE) or two- 
dimensional SWE (2D- SWE) is an established non- invasive 
technique to assess significant fibrosis in patients with chronic 
liver disease.7–13 Moreover, it has proven to be a useful surrogate 
marker to diagnose clinically significant portal hypertension,14 
mostly shown for TE and recently for liver SWE (L- SWE).15 
Ideally, short- term and long- term risk of decompensation and 
mortality should be predicted to plan patient management. Also, 
decompensated patients with ascites may have a different natural 
course of disease.16 Some patients may improve and not require 
intensified care. Since LSM not only reflects fibrosis or portal 
hypertension but also inflammation,3 11 and given that inflam-
mation is a marker of disease progression, LSM could be used as 
a predictive tool for outcomes in decompensated patients.16–18 
While LSM has been used previously to predict clinical decom-
pensation and death in patients with compensated ACLD, data 
in decompensated patients are lacking. This is mostly due to 
TE’s technical limitations, which cannot be applied to patients 
with ascites. L- SWE is not affected by ascites and can be applied 
to evaluate LSM similar to TE,12 19 20 and it has the additional 
benefit of using ultrasound for HCC screening and portal vein 
evaluation (one- stop- shop examination).21 22
Therefore, the aim of this multicentre observational study was 
to provide a simple algorithm using L- SWE for risk stratification 
of all patients with ACLD, including decompensated patients 
with ascites.
METHOD AND PATIENTS
Study design and participants
We established a derivation cohort from a multicentre interna-
tional study conducted in 16 centres, 14 of which are located 
in Europe, and two in China. Patients aged over 18 years, with 
suspected or confirmed chronic liver disease of viral and/or 
steatotic origin, requiring percutaneous liver biopsy, or who had 
received a liver ultrasound at baseline, were screened from July 
2007 to September 2017. Inclusion criteria were presence of 
ACLD of any aetiology as defined in the Baveno VI concensus,14 
valid LSM measured by 2D- SWE at baseline, and at least 28 
days of follow- up of outcome after the index L- SWE measure-
ment. All of the enrolled patients received standard treatment 
according to the respective hospital protocols. The flow chart 
of patient enrolment is depicted in online supplemental figure 1. 
Some patients of this cohort were included in another, recently 
published study.23 The number of patients from each partici-
pating centre as well as intercentre and interobserver reliability 
are shown in online supplemental tables 1 and 2. In centres 
where L- SWE is not the standard of care, patients signed written 
informed consent. The study has been registered in  Clinical-
Trials. gov as NCT03389152.
Clinical and laboratory parameters were assessed at baseline. 
These included demographic data, aetiologies, clinical decom-
pensations (hepatic encephalopathy, ascites, variceal bleeding, 
hepatorenal syndrome, spontaneous bacterial peritonitis and/or 
other infections), routine blood tests, liver, kidney and coagu-
lation function parameters and mean values of the various elas-
tography measurements. Definitions of the non- invasive scores 
including fibrosis-4 index (FIB-4), aspartate aminotransferase to 
platelet count ratio index (APRI) and albumin- bilirubin score 
(ALBI) at baseline were shown in online supplemental methods.
2D-SWE and TE procedure and additional cohort of p-SWE
L- SWE measurements were conducted according to the Euro-
pean Federation of Societies for Ultrasound in Medicine and 
Biology.24 One- dimension TE was measured using Fibroscan 
(Echosens, Paris, France). TE measurements were performed at 
baseline as per EASL- ALEH clinical practice guideline.3 20 Details 
of the procedure for 2D- SWE and TE in derivation cohort are 
summarised in online supplemental methods.
An additional cohort from the Medical University of Vienna 
undergoing LSM by p- SWE was included (online supplemental 
figure 1). The same clinical data were obtained from 121 patients 
from September 2017 to January 2020, and 119 patients were 
finally included into analysis. The protocol for pSWE of the 
liver utilising the Elast PQ module on the Philips system was 
previously described25 26 and is found in online supplemental 
methods.
Outcome evaluation
After L- SWE measurement, the study patients were regularly 
followed for at least 28 days. The primary outcome was all- 
cause mortality of the patients in the cohort with 2D- SWE, and 
mortality or liver transplantation in the cohort with p- SWE. 
Development or worsening of complications and decompensa-
tions were assessed and recorded during follow- up and were set 
as the secondary outcome. Hepatic encephalopathy was assessed 
and scored according to West Haven criteria in the follow- up 
hospital admission.27 Worsening of ascites was recorded by phys-
ical examination and abdominal ultrasound. Episodes of variceal 
bleeding, hepatorenal syndrome and bacterial infections were 
assessed and recorded during follow- up and compared with 
baseline decompensation.
Statistical analysis
Data were presented as median with IQR or number with 
percentage. Mann- Whitney test or χ2 test was used for intergroup 
comparison where appropriate. We followed the Transparent 
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► This study provides a straightforward algorithm for bed- side 
stratification of patients with ACLD based on MELD and 
L- SWE.
 ► Patients with L- SWE ≥20kPa combined with MELD ≥10 
should be followed closely and receive more intensified 
care, while patients with low risk may be managed at longer 
intervals.
 ► The M10LS20 algorithm supports clinicians in identifying 
populations at low- risk for complications as well as mortality, 
possibly enabling sparing of health care resources.
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Reporting of a Multivariable Prediction Model for Individual 
Prognosis or Diagnosis statement for multivariate prediction 
model development and validation. Univariate and multivariate 
Cox proportional hazard regression analyses were performed 
to identify independent predictors of survival. We evaluated all 
potential risk factors in our regression analysis from a literature 
review, and the variables included are shown in online supple-
mental table 3. Patients with missing data or lost to follow- up 
were excluded in the corresponding analysis (online supple-
mental table 4). The cumulative incidence curve for secondary 
outcome of decompensations were plotted and compared using 
Gray’s test with death as the competing event.
For the selection of cut- off values, we evaluated the receiver’s 
operating characteristics (ROC) of vital status at 2 years, and 
the highest Youden index was determined. Sensitivity, specificity, 
positive predictive value and negative predictive value (NPV) 
were calculated together with 95% CI of each cut- off value. 
Model performance was assessed in the 2D- SWE and the addi-
tional p- SWE cohorts. Discrimination parameters, including the 
time- dependent area under the ROC (AUROC) curve, integrated 
AUROC and Uno’s C statistic, were evaluated and compared. 
Calibration was assessed using 10- fold cross- validation with 200 
times of bootstrapping.
A p<0.05 was considered statistically significant. All statistical 
analyses were performed with SPSS V.25.0 (SPSS), R (V.4.0, R 
core team, Austria), and SAS V.9.4 (SAS Institute).
RESULTS
General characteristics of compensated and decompensated 
patients
A total of 2148 patients from 16 centres were screened in the 
derivation cohort with 2D- SWE, 2032 of whom had valid 
L- SWE assessment at baseline. Eventually, 1827 patients with at 
least 28 days of follow- up were included in the study (online 
supplemental figure 1). The median follow- up was 33.1 (IQR 
16.7–48.8) months. Baseline characteristics and follow- up 
measurements of all patients enrolled are summarised in table 1. 
Patient age was 55 years in median (IQR: 45.9–62.7), and the 
majority were male (62%). Of the enrolled patients, alcohol- 
related chronic liver disease accounted for 26.8% of cases, 
followed by non- alcoholic fatty liver disease (NAFLD) (25.2%) 
and hepatitis C virus- related (HCV) liver disease (17.3%, of 
which 16.8% sustained virological response patients). The 
median MELD score of all patients was 8 (IQR: 6–10), and the 
Child- Pugh score was 5 (IQR: 5–6). Patients included in the 
study had a median L- SWE value of 11.8 kPa (IQR: 7.4–24.5) 
(online supplemental figure 2). The haemodynamic baseline data 
of a subgroup of the patients is shown in online supplemental 
table 5.
Of the 1490 (81.6%) patients who were compensated at base-
line, 174 (11.7%) decompensated during follow- up. Of the 337 
(28.4%) patients who were decompensated at baseline, 106 
(31.5%) developed further episodes of decompensations during 
follow- up as defined elsewhere.16 The decompensated patients 
(at baseline) had significantly higher L- SWE (median 30.3 kPa 
vs 9.7 kPa, p<0.001) and TE (median 23.4 kPa vs 8.3 kPa, 
p=0.017) value at baseline than the compensated patients.
L-SWE measurement is an independent risk factor of long-
term mortality
Considering all patients with valid L- SWE measurements and 
follow- up data, the overall 28- day, 90- day, 1- year and 2- year 
mortality rates were 0.4%, 1.1%, 2.9% and 7.8%, respectively. 
As shown by the univariate and multivariate Cox regression 
models in online supplemental table 6, the LSM value with 
L- SWE was independently associated with long- term mortality 
in compensated patients (2- year HR: 1. 019, 95% CI 1.010 to 
1.028, p<0.001) and all patients included (2- year HR: 1.019, 
95% CI 1.008 to 1.030, p=0.001). If adjusted by MELD score, 
L- SWE remained an independent risk factor for 28- day, 90- day 
and 2- year mortality (table 2). L- SWE was also shown to be an 
independent risk factor in decompensated patients, in short- 
term as well as long- term follow- up (online supplemental tables 
6 and 7).
Model performance of L-SWE in combination with MELD 
score and best cut-off values
Online supplemental figure 3 shows the highest AUC of L- SWE 
combined with MELD score and compared with ALBI, FIB4 and 
APRI score. Figure 1 and online supplemental figure 4A show 
the model performance of L- SWE combined with MELD score. 
Among compensated patients, the MELD score combined with 
L- SWE (integrated AUC: 0.81) had a better time- dependent AUC 
than the MELD score alone (integrated AUC:0.73), especially in 
long- term follow- up. Interestingly, the c- index of the combined 
model (0.825) is significantly higher than that of the MELD and 
the Child- Pugh score (p=0.0329 and p<0.0001, respectively). 
Similar results were obtained in all of the included patients. The 
combined model was well calibrated, as shown in online supple-
mental figure 4B.
To further stratify the 2- year risk of mortality, the best cut- off 
value of 10 points for the MELD score and best cut- off value 
of 20 kPa for L- SWE was found with the highest Youden index 
in compensated patients and all patients (online supplemental 
tables 8–10). Moreover, in the group with an MELD score <10 
and those with an MELD score ≥10, significant differences 
(log- rank p<0.001) were found between patients with L- SWE 
measurements above and below 20 kPa over 2 years in Kaplan- 
Meier curves (online supplemental figure 4C,D).
Stratification M10LS20 algorithm with L-SWE and MELD score 
in compensated and decompensated patients
With the two cut- off values found for the MELD score and 
L- SWE, respectively, the algorithm (M10LS20) of a combina-
tion of L- SWE value and MELD score could easily stratify the 
patients into three different risks group, namely (1) patients with 
L- SWE measurements <20 kPa and an MELD score <10 (good 
prognosis group, 56.7%), (2) patients with L- SWE measure-
ments ≥20 kPa and an MELD score ≥10 (poor prognosis group, 
25.0%) and (3) the remaining patients (intermediate prog-
nosis group, 18.3%). According to the Kaplan- Meier curve in 
figure 2A, the three groups have significantly different survival 
rates (p<0.001) both at short- term (90 days) and long- term 
follow- up (2 years) in compensated patients. The significant 
survival differences were also found in decompensated patients 
and in all patients (figure 2B and C). Interestingly, the density 
curve of time distribution of mortality shown in online supple-
mental figure 5A confirms that the algorithm identifies groups 
with different median survival time. The mean time to death was 
11 months in the poor prognosis group, while it was 16 months 
in the good prognosis group.
Predictive value of L-SWE combined with MELD score for first 
or further decompensation
As expected, the three groups showed significantly different 
median baseline L- SWE values of 8.2 kPa, 21.1 kPa and 36.0 kPa 
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(p<0.001) in the good prognosis, the intermediate prognosis, 
and the poor prognosis group (online supplemental figure 5B), 
respectively. Of the 1827 study patients, 182 patients developed 
new episodes of decompensations or worsening of ascites or HE 
during the 2- year follow- up period.
Among the patients without decompensation, the model of 
L- SWE and MELD score had the best AUROC in the predic-
tion of decompensation development during the follow- up, 
compared with the MELD score and the Child- Pugh score 
(online supplemental figure 6A).
When considering death as a competing risk factor for 
developing or worsening of decompensation, L- SWE value 
at baseline appeared to be a statistically significant indepen-
dent risk factor in the outcome of developing decompensa-
tion, after adjustment for age, MELD score, and Child- Pugh 
score at baseline (HR 1.020 (95% CI 1.014 to 1.026), 
p=0.001) (online supplemental table 11). Moreover, in 
the patient groups with an MELD score< or ≥ 10 points, 
L- SWE (cutoff ≥20 kPa) could best stratify the cumulative 
incidence of decompensation for up to 2 years (Gray’s test 
p<0.001) (online supplemental figure 6B,C).
Using the M10LS20 algorithm, we could also stratify the 
patients into three risk groups for risk of decompensation: 
(1) good prognosis, (2) intermediate prognosis and (3) poor 
prognosis. Of the compensated patients, the group with poor 
prognosis had the highest incidence of development of decom-
pensation (figure 3A). The cumulative incidence curves with 
Gray’s test also showed significant differences in the develop-
ment or worsening of ascites (p<0.001) and hepatic encephalop-
athy (p<0.001) in these three risk groups (online supplemental 
figure 7A,B). Nevertheless, in decompensated patients, signif-
icant differences were also found in the risk of worsening of 
decompensation in these three groups (Gray’s test p=0.0025) 
(figure 3B). In the whole cohort, a similar effect was confirmed 
(figure 3C).
Validation of the stratification M10LS20 algorithm using 
p-SWE
The baseline characteristics of the add groups with p- SWE are 
shown in online supplemental table 12). Patients in the addi-
tional cohort had higher L- SWE measured by pSWE than the 
2D- SWE derivation cohort and had a higher MELD score. The 
pSWE combined with the MELD score model well calibrated in 
the additional cohort (online supplemental figure 8A) and had 
an integrated time- dependent AUC of 0.8407 (figure 4A and 
online supplemental figure 8B).
The validity of the M10LS20 algorithm using p- SWE tech-
nology was confirmed by a significant survival difference in 
the three prognosis groups in the additional cohort, with 
a log- rank p of 0.032 (figure 4B). When considering death 
as a competing risk for decompensation, the cumulative 
incidence of development or worsening of decompensation 
also showed significant differences in these three groups 
(figure 4C). Interestingly, a similar decision tree could be 
established in the additional cohorts, stratifying the ACLD 
patients into three distinct prognosis groups (online supple-
mental figure 9).
Internal validation of the stratification M10LS20 algorithm in 
compensated and decompensated patients
For internal validation of our stratification algorithm in both 
compensated and decompensated patients, the combined 
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Figure 1 (A) Time- dependent area under the curve and 95% CI of the combined algorithm based on MELD score and SEW, and MELD score alone in 
compensated patients only during 2 years of follow- up. (B) Time- dependent area under the curve and 95% CI of the combined model of MELD score 
and swe, and MELD score alone in all patients (including decompensated patients at baseline) of the cohort with 2D- SWE during 2 years of follow- up. 
2D- SWE, 2- dimensional shear wave elastography; AUC, area under the curve; MELD, the model for end- stage liver disease.
 on A
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Figure 2 Curves of patients with good, intermediate and poor prognosis. (A) Kaplan- Meier of 2- year survival curve in compensated patients. Level 
of significance: log- rank p<0.001. (B) Kaplan- Meier of 2 years survival curve in decompensated patients. Level of significance: log- rank p=0.003.
(C) Kaplan- Meier of 2- year and 90- day survival curve of all patients of the cohort with 2D- SWE measurements. The top left rectangle in the curve 
of 2 years survival indicates the area of the Kaplan- Meier curve of 90- day survival depicted in the bottom left panel. Level of significance: log- rank 
p<0.001. 2D- SWE, 2- dimensional shear wave elastography.
 on A
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Figure 3 (A) Cumulative incidence of development of decompensations within 2 years of patients with good, intermediate and poor prognosis in 
compensated patients. Level of significance: Gray’s test p<0.0001. (B) Cumulative incidence of development of further episodes of decompensation 
within 2 years of decompensated patients with good, intermediate and poor prognosis. Level of significance: Gray’s test p=0.0025. (C) Cumulative 
incidence of development of decompensations within 2 years of all patients included in the cohort with 2D- SWE measurements with good, 
intermediate and poor prognosis. Level of significance: Gray’s test p<0.0001. 2D- SWE, 2- dimensional shear wave elastography.
 on A
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Figure 4 (A) Time- dependent area under the curve and 95% CI of the combined model of MELD score and p- SWE in the additional cohort validated 
for p- SWE during 2 years of follow- up. (B) Two- year Kaplan- Meier curves of the additional cohort validated for p- SWE of patients classified with good, 
intermediate and poor prognosis. Level of significance: log- rank p<0.032. (C) Cumulative incidence of development of decompensations within 2 
years of all patients included in the additional cohort validated for p- SWE with good, intermediate and poor prognosis. Level of significance: Gray’s 
test p=0.0025. AUC, area under the curve; MELD, model for end- stage liver disease; p- SWE, point shear wave elastography.
 on A
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a 2/3 internal derivation cohort and a 1/3 internal validation 
cohort. This was performed for both compensated patients and 
decompensated patients. The baseline characteristics of both 
cohorts are listed in online supplemental tables 13 and 14).
Regardless whether compensated (log rank p<0.001) or 
decompensated (log rank p=0.042) were considered, signifi-
cantly different survival functions were detected in the three 
different risk groups from the derivation cohorts. The strategy 
was subsequently validated in the 1/3 internal validation 
cohort, showing a significant risk of mortality within 2 years 
(log rank p<0.001 and p=0.038 in compensated and decom-
pensated patients, respectively) (online supplemental figures 
10 and 11).
The decision tree (figure 5) shows the strategy (M10LS20 
algorithm) used for mortality risk prediction stratification in the 
combined cohort of cohorts with 2D- SWE and the additional 
cohort with pSWE. It can also be applied for decompensation, 
evidenced by the significantly different incidences of decompen-
sation in these three risk groups (3.5%, 18.8% and 61.8% within 
2 years, respectively).
Validation of the stratification M10LS20 algorithm using TE 
and MELD score
Of the patients included in the cohort with 2D- SWE, 754 
patients had LSM by TE at baseline. The median TE value was 
8.3 kPa. As expected, decompensated patients had a significantly 
higher TE value than compensated patients (23.4 kPa vs8.3 kPa, 
p=0.017).
In the multivariate analysis adjusted by the MELD score, liver 
stiffness proved to be an independent risk factor predicting 
2- year mortality (online supplemental table 15). TE could 
equally predict the long- term risk of death compared with SWE, 
as shown by similar time- dependent ROC (online supplemental 
figure 12A). Performance of the model of TE combined with the 
MELD score was also similar to 2D- SWE combined with the 
MELD score (online supplemental figure 12B).
The same algorithm of M10LS20 was applied in patients with 
TE measurement and MELD score, using the same cut- off of 20 
kPa for TE. As depicted in online supplemental figure 9), the 
cut- off of 20 kPa could also stratify patients with the distinct 
outcome of death in patients with an MELD score above as well 
Figure 5 Stratification model of cohort with 2D- SWE and additional cohort with p- SWE for prediction of estimated mortality (upper panel) at 28 
and 90 days as well as at one and 2 years of follow- up based on MELD score <10 vs ≥10 and L- SWE <20 vs ≥20 kPa; stratification model of cohort 
with 2D- SWE and additional cohort with p- SWE for prediction of first/further decompensation risk (lower panel) at 28 and 90 days as well as at one 
and 2 years of follow- up based on MELD score <10 vs ≥10 and L- SWE <20 vs ≥20 kPa. 2D- SWE, 2- dimensional shear wave elastography’ L- SWE, liver 
SWE; MELD, model for end stage liver disease; p- SWE, point SWE.
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as an MELD score below ten points. In fact, using the same 
algorithm and cutoffs, three distinct groups with significantly 
different mortality risks could be identified (online supplemental 
figure 13).
Aetiological sensitivity, regional sensitivity and time-period 
sensitivity analysis of the stratification M10LS20 algorithm
Interestingly, the M10LS20 algorithm was confirmed in all 
patients with different aetiologies. As shown in online supple-
mental figure 14), patients with good prognosis, intermediate 
prognosis and poor prognosis had significantly different survival 
probability, regardless of aetiology as analysed separately for 
alcoholic- related liver disease, HCV, hepatitis B virus (HBV) and 
NAFLD.
When we divided the cohort with 2D- SWE into patients from 
Southern Europe and Northern Europe, the model still showed 
the highest AUROC (online supplemental figure 15A,B). Patients 
from Southern Europe as well as Northern Europe could be 
adequately stratified by the M10LS20 algorithm (online supple-
mental figure 15C,D).
Since our derivation cohort of 2D- SWE and the additional 
cohort with p- SWE were included from 2007 to 2020, we 
divided our cohorts into three subgroups according to different 
time periods of inclusion (online supplemental figure 16). The 
M10LS20 algorithm performed equally well regardless of the 
time period of inclusion, as demonstrated by the significantly 
different survival curves in the three stratified risk groups. 
Furthermore, patients with second follow- up L- SWE measure-
ments were analysed. As shown in online supplemental figure 
17), the majority of patients with good prognosis and poor prog-
nosis remained within the same stratification group when using 
the M10LS20 algorithm during the follow- up. Similar results 
were also found in the intermediate group.
Discussion
This international multicentre cohort study establishes and vali-
dates that the combination of MELD score with LSM measured 
by SWE (M10LS20 algorithm) is an accurate and easy tool for 
stratification of ACLD. In the study, mortality and risk of decom-
pensation in patients with L- SWE measurements below 20 kPa 
and an MELD score below 10 were 1.1% and 3.5%, respectively, 
while patients with L- SWE measurements above 20 kPa and an 
MELD score above 10 had a very high risk of mortality and 
decompensation (36.9% and 61.8%, respectively).
Patients with ACLD represent a large and heterogeneous 
population with various aetiologies, such as alcoholic- related 
liver disease, NAFLD, chronic viral hepatitis and autoimmune 
liver disease. Many patients deteriorate rapidly due to severe 
complications and decompensating episodes and may die within 
a short period of time. However, even patients with ascites can 
recompensate and show a very low rate of further decompen-
sation.16 Therefore, in addition to clinical history, an accurate 
and practical tool to assess and predict short- term and long- 
term outcome in patients with high heterogeneity is urgently 
required. Such a tool can greatly help clinicians to stratify treat-
ment options and reduce waste of medical resources. To identify 
such a tool for prediction of outcome, the mechanism leading 
to decompensations and death must first be identified. There 
is abundant evidence that advanced fibrosis is associated with 
progression towards decompensations in ACLD.28–30 Moreover, 
portal hypertension is a driver of decompensation and death.31 32 
Finally, systemic inflammation has been identified in multiple 
studies as a major cause of decompensation, acute- on- chronic 
liver failure and death.16 33 Of note, systemic inflammation can 
already be present in the early stages of ACLD.18 34 Interest-
ingly, hepatic fibrosis and inflammation are major components 
of liver stiffness.3 11 19 35 Although LSM by TE is currently the 
most widely used method, it has the limitation of a high failure 
rate mostly due to obesity or ascites.12 36 Our data suggest that 
L- SWE is useful in this complex setting. Moreover, the algo-
rithm we established for L- SWE was also confirmed with LSM 
performed by TE in our study.
Additional prognostic factors in cirrhosis include the severity 
of liver failure and extrahepatic organ failure (eg, kidney and 
coagulation failure).37 38 These markers are reflected in the 
MELD score.2 To date, no easy algorithm has been available to 
stratify the risk of decompensation and mortality. Patients with 
an MELD score below 15 are the most heterogeneous in terms of 
clinical evolution and are especially at risk of being overlooked 
since 15 points is the cut- off value for putting forward the indi-
cation for liver transplantation.39
Our data show that LSM by 2D- SWE measurement is an 
independent risk predictor of death and has a high accuracy in 
predicting 2- year mortality. We could show that a combination 
of L- SWE and MELD score has the highest AUROC, superior 
to L- SWE alone, MELD score and Child- Pugh score. Thus, a 
combination of L- SWE and MELD score is an accurate tool to 
stratify patients with a high risk of death within 2 years. Further-
more, increased L- SWE measurements correlated with the devel-
opment or further episodes of decompensation. Importantly, 
this large- scale multicentre study enabled the identification of 
an easy- to- memorise cut- off value of 10 for the MELD score and 
20 kPa for L- SWE to classify heterogeneous ACLD patients into 
three groups with completely distinct risks of mortality. Interest-
ingly, this cut- off value is identical to the one provided by several 
studies on the diagnosis of clinically significant portal hyperten-
sion.7 11 40 The extremely high NPV (98%) indicates that this 
cut- off value can help clinicians exclude low- risk populations, 
emphasising its potential role in saving clinical resources.
A further important finding of this study is that L- SWE had 
predictive value for the development or worsening of decom-
pensation, which has been missing to date. Especially in patients 
with ascites, which defines decompensation, this algorithm is 
very useful.41 Our findings are in agreement with previous data 
suggesting that values of LSM indicating the presence of clin-
ically significant portal hypertension (a major factor driving 
decompensation in cirrhosis13 42 predict clinical decompensation. 
We confirm that this holds true across different aetiologies and 
stages of disease. Thus, the present study may fill the knowledge 
gap of the usefulness of L- SWE in the prediction of complica-
tions. From a practical point of view, routine use of L- SWE could 
provide early identification of patients at risk of poor outcomes, 
thus helping to tailor treatment options. Since non- selective beta- 
blockers have recently been shown to be effective in reducing 
clinical decompensation in patients with compensated cirrhosis 
and clinically significant portal hypertension irrespective of the 
size of varices,43 L- SWE may be used to non- invasively select 
patients who could benefit from this treatment.
Of note, the M10LS20 algorithm was found to be accurate 
not only in compensated but also in decompensated patients. 
We further validated this innovative algorithm in an additional 
cohort with LSM measured by pSWE and confirmed the robust-
ness and wide range of its application. The sensitivity analysis 
was also done in heterogeneous aetiologies and by different 
participating centres from various regions worldwide. Interest-
ingly, there was no impact of aetiology on the performance and 
applicability of our algorithm. The M10LS20 algorithm was 
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found to be robust for any aetiology, including alcohol- related 
liver diseases, chronic hepatitis C, chronic hepatitis B and non- 
alcoholic fatty liver disease. Hence, it has been demonstrated 
that the M10LS20 algorithm is appropriate for universal use 
and can be easily applied in daily clinical practice. This easy 
algorithm may affect the time interval for outpatient follow- up 
treatment in patients. Thus, patients with poor prognosis and 
at high risk of mortality should be seen more frequently (eg, 
every 2–3 months), while in patients with intermediate risk 
the frequency of visits could be lower (eg, every 3–6 months), 
and patients with good prognosis are only to be seen every 6–8 
months. Especially in times when person- to- person contact must 
be reduced, for example, during a pandemic, this algorithm can 
be applied successfully.44 As a result, patients with chronic liver 
diseases would follow a more individualised clinical path after 
elastography evaluation and liver- related risk evaluation using 
the MELD score.
Despite the fact that our study is a large international multi-
centre study, it has several limitations. First, it is an observational 
study and, although the standard procedure of L- SWE measure-
ment was followed in the centres, the size of the region of 
interest of L- SWE was freely chosen by the operator within the 
quality range in their clinical practice. However, excellent reli-
ability was found in most of the operators and centres as shown 
by an intraclass correlation coefficient of above 90%. Second, 
the long time period of inclusion of this study could impact the 
results. However, when we stratified our patients into subgroups 
with different time periods of inclusion, we found that the 
M10LS20 algorithm could be accurately used in all subgroups. 
Additionally, we established a cut- off value in the study cohort 
with 2D- SWE, and further validated it using different tech-
niques, including limited numbers of TE measurements and an 
additional cohort with p- SWE. While an external multicentre 
study is called for to exclude bias, our study reflects various real- 
life scenarios, strengthening its applicability and validity.
In conclusion, this study shows for the first time that L- SWE 
predicts mortality in patients with chronic liver disease regardless 
of aetiologies. An MELD score above 10 combined with L- SWE 
measurements above 20 kPa could help to stratify mortality and 
decompensation risk and guide patient management.
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